If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Forteo® (teriparatide [rDNA origin] injection) has only been tested for use through 28 days; therefore, do not use a teriparatide delivery device beyond 28 days from the first injection (Forteo Package Insert, 2012).
Discard the teriparatide delivery device after the 28 day in-use period, even if there is still medication left (Forteo Package Insert, 2012).
Use of Teriparatide Beyond 28 Days
Accidental use of teriparatide beyond 28 days is not likely to cause harm, however, is not recommended due to the information provided below.
Teriparatide contains preservatives which help protect against germs.
Beyond 28 days, the preservatives may not work as well, potentially allowing germs to grow in the liquid medicine in the delivery device.
It is possible that teriparatide may not work as well after 28 days as growth of germs may cause the medicine to begin to breakdown.
Therefore, products with preservative, such as teriparatide, should not be used beyond 28 days.
European Medicines Agency Recommendation
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommends that in-use sterile solutions be used within 28 days due to the potential for reduced sterility of the medication after this time interval (EMA [WWW]).
Enclosed Prescribing Information
The published references below are available upon request by contacting 1-800-LillyRx.
FORTEO [Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2012.
The European Medicines Agency: Committee for Medicinal Products for Human Use. Available at: www.ema.europa.eu
Date of Last Review: February 12, 2017